Rosenblat T, McDevitt M, Mulford D, Pandit-Taskar N, Divgi C, Panageas K
Clin Cancer Res. 2010; 16(21):5303-11.
PMID: 20858843
PMC: 2970691.
DOI: 10.1158/1078-0432.CCR-10-0382.
Johnson S
Clin Pharmacokinet. 2000; 39(1):5-26.
PMID: 10926348
DOI: 10.2165/00003088-200039010-00002.
CAPIZZI R
Invest New Drugs. 1996; 14(3):249-56.
PMID: 8958179
DOI: 10.1007/BF00194527.
SCHULMAN P, Budman D, Vinciguerra V, DEGNAN T
Cancer Chemother Pharmacol. 1980; 5(1):67-9.
PMID: 7460196
DOI: 10.1007/BF00578565.
Urquhart J
Drugs. 1982; 23(3):207-26.
PMID: 7042294
DOI: 10.2165/00003495-198223030-00003.
Subcutaneous infusion of cytosine arabinoside. A practical alternative to intravenous infusion.
Slevin M, Piall E, Aherne G, Johnston A, Lister T
Cancer Chemother Pharmacol. 1983; 10(2):112-4.
PMID: 6572569
DOI: 10.1007/BF00446221.
The pharmacokinetics of subcutaneous bolus cytosine arabinoside in an arachis oil plus aluminium distearate suspension.
Slevin M, Piall E, Johnston A, Levison D, Aherne G, Tree S
Invest New Drugs. 1984; 2(3):271-6.
PMID: 6511233
DOI: 10.1007/BF00175376.
Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide.
Gore M, Powles R, Lakhani A, Milan S, Maitland J, Goss G
Cancer Chemother Pharmacol. 1989; 23(6):373-6.
PMID: 2653659
DOI: 10.1007/BF00435839.
[Pharmakokinetics of hydroxy-urea. Therapy of acute myeoblastic leukemias using synchronization and recruitment effects (author' transl)].
Sauer H, Pelka R, Wilmanns W
Klin Wochenschr. 1976; 54(5):203-9.
PMID: 1062636
DOI: 10.1007/BF01469126.
[Present state in synchronization therapy of malignant tumors and acute leukemias (author's transl)].
Sauer H, Wilmanns W
Klin Wochenschr. 1976; 54(5):197-202.
PMID: 768630
DOI: 10.1007/BF01469125.
Remission induction and remission maintenance in adult acute nonlymphocytic leukemia employing a modified cytostatic (COAP) regimen.
Gerecke D, Hirschmann W, Voigtmann R, Gross R
Blut. 1979; 39(1):39-45.
PMID: 465742
DOI: 10.1007/BF01008073.
